by ilene - July 27th, 2010 4:10 pm
Over the past few years, there has been a lot of talk about pharmaceutical manufacturing and persistant problems in quality control. Genzyme, Schering Plough, are ones that comes to mind, but now Johnson & Johnson came under fire. Manufacturing is a killer for any pharmaceutical company, as news breaks, companies scramble, and CEOs come on saying that everything is OK, and we are going to recall the product and get things fixed. Unfortunately, those fixes take a lot longer than one would think, and in the case of a company as diverse as Johnson & Johnson (NYSE:JNJ), their current crisis is a good one.
Johnson & Johnson is a global American pharmaceutical, medical devices and consumer packaged goods manufacturer founded in 1886. The corporation’s headquarters is located in New Brunswick, New Jersey, United States. Its consumer division is located in Skillman, New Jersey. The corporation includes some 250 subsidiary companies with operations in over 57 countries. Its products are sold in over 175 countries. J&J had worldwide pharmaceutical sales of $22.5 billion for the full-year 2009 represented a decrease of 8.3% versus the prior year. Net earnings and diluted earnings per share for the full-year 2009 were $12.3 billion and $4.40. Full-year 2009 net earnings included an after-tax restructuring charge of $852 million and an after-tax gain of $212 million representing the net impact of litigation matters. Full-year 2008 net earnings included special items related to in-process research and development charges of $181 million with no tax benefit and an after-tax gain of $229 million representing the net impact of litigation matters. Excluding these special items, net earnings for the full-year 2009 were $12.9 billion. Diluted earnings per share for the full-year 2009 were $4.63, representing an increase of 1.8%, as compared with the full-year in 2008.
The Company announced earnings guidance for full-year 2010 of $4.85 to $4.95 per share, which excludes the impact of special items.
In 2010, a suit brought by the United States Department of Justice alleges that the company from 1999 to 2004 illegally marketed drugs to Omnicare, a pharmacy that dispenses the drugs in nursing homes. JnJ is vigorously fighting this claim, but I think they will settle it out of court. More recently JnJ has broadened their recall children’s medications for a manufacturing issue…
by ilene - July 25th, 2010 2:54 am
Courtesy of Pharmboy
At PSW, we have been hemming and hawing about inflation/deflation, how to right Washington, oil exploration, solar flairs, irrational exhuberance in the market, and why Gilead (GILD) has lost its prominence in the market’s eye. Experts say it is the company’s pipeline, as one of its flagship drugs is expiring in 2013. Others allege that the company is being shorted by hedge funds because the short interest is currently trading at 1 day.
Gilead Sciences, founded in 1987, is a leading pharmaceutical player, with more than 2,500 employees. With headquarters in Foster City, California, and operations spanning across the globe, it focuses its research and clinical programs on antivirals, antifungals and antibacterials. Gilead’s portfolio of 13 marketed products includes a number of category firsts and market leaders.
Gilead’s first significant entrant into the HIV market in 2001 was Viread (a nucleotide analog reverse transcriptase inhibitor, or NtRTI). Viread was recently approved for the treatment of chronic hepatitis B. It was followed in 2003 by Emtriva, and then in 2004, Gilead’s current blockbuster product Truvada (a combination of Viread and Emtriva) was launched. Gilead’s newest HIV product is Atripla, a combination of Truvada and Bristol-Myers Squibb’s (BMS) Sustiva, which has achieved rapid sales uptake since its launch in 2006. Below are Gilead’s main income drivers, and as one notices, the HIV franchise is the majority of the company’s income.
In July 2009, Gilead announced a collaboration with Tibotec (a division of t Johnson & Johnson) to develop and commercialize a fixed-dose combination (FDC) of Truvada and Tibotec’s TMC278 (rilpivirine). This decision was to develop, in essence, a second generation Atripla. This was a wise move by Gilead because GSK has its own integrase inhibitor, GSK1349572, which has shown positive Phase II results and will eventually compete with GILD/JNJ’s fixed dose combination. In addition, GILD will lose patent protection on Atripla in 2013, so doctors (or GSK) could combine the new GSK drug with BMS/s Sustiva, thus inceasing the pricing pressure on GILD. Teaming with JnJ should help maintain Gilead’s already dominant FDC market share which is projected to be 40% of the HIV market.
by ilene - June 1st, 2010 7:53 pm
Courtesy of Pharmboy
Here at Phil’s Stock World, we try to offer the best of all possible worlds. Phil has the rounded techniques of using options, covered calls, shorting and overall market direction to a prime. David Ristau gives us one up and one down pick of the day for 2-3% gains (he has been on a roll), and Optrader satisfies the swing trades. And then there is me, Pharmboy. I try to investigate the science behind the scenes to give the best possible chances to our readers on entering stocks we think will be profitable trades.
Take Ariad (ARIA), which I wrote about in August 2009. We had several different approaches, but the favorite was buying the stock at $1.30, selling and equal amount of the February 2010 $2.50 puts and calls which if the stock was $2.50 or above on OPEX, one would have made 68% ( in other words, 100 shares of stock with 1 call and 1 put sold would have gained 68% of the original $1.90). Where did ARIA finish up on the February OPEX…. $2.54. Lucky, somewhat on the OPEX play, but ARIA has been one of the core biotech holdings at PSW, along with DCTH (we jumped on this stock at about $5), CRIS (in at $1.21), KERX, and QCOR. Now, not all are perfect, as we have had a few that have gone south on us, most notably GILD. (Actually, Optrader correctly picked the direction on them a week back and I should have paid more attention to his 5d MA strategy.)
PSW has a great group of traders and investors that are willing to offer advice and point to better option and stock plays for all to benefit. As Phil notes, the more eyes on the charts and the market gives us the distinct advantage to play the game with them, not against!
Next, on to a few picks that could have us very happy in the next 6-18 months….
The picks I am outlining today are a bit more risky than past posts, but I believe they have the potential to make it to the game. They may not be a market leader, or the next Genentech, but I believe they have the right ‘products’ in place if management acts…
by Chart School - April 28th, 2010 9:49 pm
Courtesy of Pharmboy
Gaps are very profitable technical indicators. A gap is an area on a chart where no trades take place and these are caused by fundamental or technical events that usually occur after the market closes and before the market opens, also known as ‘non-regular trading hours’ (NRTH’s). There are four basic gap types: area, continuation, breakaway and exhaustion.
Gaps are significant for many reasons:
- Gaps tell traders that something occurred during NRTH’s. Typical events include: earnings announcements, FDA approvals, analyst upgrades/downgrades, company press releases and other significant events that may cause investors and traders to place orders to buy or sell during NRTH’s, causing an order imbalance.
- The type of gap will help you determine the probability of the stock’s direction in the short and intermediate term.
- Gaps are profitable. Traders can take advantage of the imbalance of orders by either “catching the momentum” or “fading the gap”. When riding a gap, the traders are betting that the stock will continue in the direction it gapped. When a trader fades a gap, they are betting that the gap will “fill” and move opposite of the gap’s opening direction.
Types of Gaps
Area gaps are usually small and unimportant. They are also referred to as “common gaps” because they occur so frequently. Characteristics of area gaps are that they are fill very quickly. When the word “fill” is used, traders are referring to the gap’s closure. The gaps usually occur in trading ranges and they form on very low volume. Because of the low buying volume of the stock, the gap cannot sustain itself, thus filling relatively quickly.
The easiest way to determine if a gap will fill is to watch the first 30 minutes of the day. If the candlesticks appear to be fading in the opposite direction, it’s very difficult to stop it. This is because many others see the same fade and will jump on board. Remember, a gap does not have to fill on the same day of the gap. These types of gaps are unpredictable and are hard to trade. Figure 59 an example of an area gap.
Figure 59. Area gap.
by Chart School - April 1st, 2010 2:23 pm
Links for previous chapters:
Courtesy of Pharmboy of Phil’s Stock World
In Figure 1 below, typical up trends and down trends are shown. These zigzag patterns are seen all the time, but why do they form? Let’s say someone bought a stock at a certain point. If that stock went up, but pulled back to the original purchase price, they will often think that it’s an opportunity to buy more at their original price, thus adding to their position. This is also the same for shorts when they are able to short a stock at the same price they shorted previously. Then why do peaks form? People sell (or cover) to take profits. Obviously, any increase in selling will pull the stock back. Those who bought at a lower level may start buying again. This repeats and repeats until 1) there is no more stock left for people to buy, or 2) there is too much supply and not enough buyers. On a larger scale, this is how bull and bear markets begin and end.
Figure 1 Typical up and down trends.
by ilene - February 21st, 2010 12:15 am
Fundamental vs. Technical Analysis
Courtesy of Pharmboy
There are many different ways to assess the value of a company, and the methods used to analyze securities and make investment decisions fall into two very broad categories: fundamental analysis and technical analysis. Fundamental analysis is a method of evaluating a security that entails attempting to measure its intrinsic value by examining related economic, financial and other qualitative and quantitative factors. Fundamental analysts attempt to study everything that can affect the security’s value, including macroeconomic factors (like the overall economy and industry conditions) and company-specific factors (like financial condition and management). Technical analysis takes a completely different approach. It is a method of evaluating securities by analyzing statistics generated by market activity, such as past prices and volume. Technical analysts do not attempt to measure a security’s intrinsic value, but instead use charts and other tools to identify patterns that can suggest future activity.
Figure 12. Technical analysis noted on the graph, Fundamental analysis income statement.
Out of the two, fundamental analysis is the more widespread discipline, by far. There is a lot of criticism concerning technical analysis, and the criticisms are derived from the Efficient Market Theory. The Efficent Market Theory states that the market’s current price is accurate and correct and that past information (same as charts) is already discounted into the stock. There are variations of this theory; however, most of these people believe that if technical analysis works then market efficiency may be questionable.
There are many papers, in fact, that say TA is often more reliable and profitable using a few finely derived rules. Ramazan Gençay wrote a paper entitled, “The predictability of security returns with simple technical trading rules.” Here is the abstract:
Technical traders base their analysis on the premise that the patterns in market prices are assumed to recur in the future, and thus, these patterns can be used for predictive purposes. This paper uses the daily Dow Jones Industrial Average Index from 1897 to 1988 to examine the linear and nonlinear predictability of stock market returns with simple technical trading rules. The nonlinear specification of returns are modeled by single layer feed forward networks. The results indicate strong evidence of nonlinear predictability in the stock market returns by using the past buys and sell signals of the moving…
by ilene - February 16th, 2010 10:38 pm
Here’s the second chapter from Pharmboy’s “Handbook of Technical Analysis.” If you missed the introduction and first chapter, click on “Understanding Market Cycles: The Art of Market Timing” to read from the beginning. – Ilene
Courtesy of Pharmboy of Phil’s Stock World
Technical analysis dates back hundreds of years. According to historical records, a great Japanese rice trader named Homma Munehisa (1724-1803) developed a form of TA known as candlestick charting. A candlestick chart is a style of bar-chart used primarily to describe price movements of securities, derivatives, and currencies over time. It combines aspects of a line-chart and a bar-chart, in that each bar represents the range of price movement over a given time interval. It is most often used in TA of equity and currency price patterns.
Technical analysis is an art. With focus and diligence, TA can often be learned within a short period. A chartist using TA reads and interprets chart patterns and then attempts to predict the most likely short-term outcome based on his methods. Figure 1 shows a 6 month Diamonds (DIA) candlestick chart and many patterns and studies that traders often use to enhance their trading. Moving averages convergence divergence (MACD) and relative strength index (RSI) are two studies very commonly used by technical analysts. MACD is a trend-following momentum indicator that shows the relationship between two moving averages of prices, while RSI is a technical momentum indicator that compares the magnitude of recent gains to recent losses in trying to decide overbought and oversold conditions of an asset. Because candlestick charting is the basis of this handbook, I use these types of charts almost exclusively in my examples.
In the U.S., TA first gained a following from Charles Dow’s Dow Theory in the late 19th century. The six basic tenets of Dow Theory, as summarized by Hamilton, Rhea, and Schaefer, are as follows:
Tenant 1. The market has three movements (Figure 2):
- The primary trend, or major trend, may last from less than a year to several years. It is bullish or bearish.
- A secondary trend moves in the opposite direction of the primary trend, or as a correction to the primary trend. For example, an upward primary trend will
by phil - September 30th, 2009 4:20 pm
Courtesy of Pharmboy
Good day to all! The corn is ready for harvest, and the fall season is upon our Pharm. It is time for a quick review to see how we have done, and add a few more goodies to our Plots.
From our 15-Aug-09 list:
Novartis – Buying the $40 Jan10 C @ 6.40 ($1 premium), selling $45 Sept09 for 1.35 (also $1 premium). The $40s Jan10 are now 9.10, and rolled 2X to the $50 Oct, now at $0.45 (small loss on the roll). Net ~$2.1 up for the trade.
Bristol-Myers – Buy outright for the dividend, or buying the $20 Jan10 C @ 2.80 ($0.5 premium), selling $22.5 Sept09 C @ $0.55 and $22.5 P@ $0.7. I think this company has room to run. Bought outright and the stock closed on OPEX at 22.47…..can’t get better than that……Only stock on this position, but looking to sell the Nov09 24/22 P/C for 0.44/0.75.
SNY – Not as confident on the SNY story as of yet. I would sell the $32.5 Sept09 P, being prepared to roll down to the $30 Dec09s. These expired worthless….nice gain.
JNJ Buying the $55 Jan10 C @ 6.50 ($0.5 premium), selling $60s Sept09 C/P for 2.20. $55 Jan10s currently $6.10, and the Sept P expired worthless. Sept09 C rolled to the $60 Oct09 C for a 0.50 credit. Puts not sold as of yet.
Genzyme – Buying the $50 Oct09C @ 4.2 ($1.5 premium), letting it run for the next few days, and then selling $55 Sept09 for 1.25 or better (all premium). $50 Oct09 are currently $6.80 and the $55 Sept09s were rolled up to the $57.5s almost even. These will need cashed out for a $2.5 gain, or to be adjusted to the 50 Apr10 C for 9.8. To help offset the costs, I would sell the $55 Oct09 P for $1 or better. For a net $1 out of pocket…